Cartesian Therapeutics Inc (RNAC) 13F Ownership Report (Q2 2026)

RNAC ranks #4650 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

98 institutions disclose a position in RNAC, but none treat it as a major bet — even CM Management, LLC, its most concentrated holder, allocates just 0.4% of its own portfolio to it.

Squarepoint Ops LLC has added to its RNAC position for two straight quarters, increasing it by $23.4M to reach $23.5M today.

Fidelity has trimmed its RNAC position for two straight quarters, cutting it by $6.0M while still holding $3.8M.

RNAC is down 3.3% today, but institutions show net buying of $19.3M this quarter — a divergence between today's price move and the underlying institutional flow.

RNAC reported a net loss of $151.9M over the trailing twelve months.

• Not yet profitable — net loss of $151.9M over the trailing twelve months
• Revenue grew 100.0% year over year
• Net income declined year over year, from -$36.3M to -$151.9M
• Operating cash flow was negative, using $73.9M in cash
• Current ratio of 8.65x — enough short-term assets to cover short-term liabilities